Login / Register Order My Items
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

Site-Specific Peptide–Drug Conjugation

Defined attachment strategies for custom peptide–drug conjugates (PDCs) — built for reproducibility (project-dependent).

Defined, site-specific PDC synthesis to reduce heterogeneity (project-dependent).

Request a Quote Contact a Chemist
Talk to a chemist Request a quote
Overview Why site-specific Attachment strategies Linkers Workflow QC Related services Quality FAQ Reading Contact

Overview

Site-specific peptide–drug conjugation is the controlled attachment of a small‑molecule drug payload to a peptide at a single, predefined position to produce a chemically uniform peptide–drug conjugate (PDC). Unlike random modification (which can generate mixtures of attachment-site isomers), site-defined strategies are used to reduce heterogeneity and improve reproducibility for research programs. [1]

In typical PDC designs, the peptide can function as a targeting ligand, cell-penetrating element, or scaffold, while the payload provides the desired biological activity. The attachment site (N‑terminus, C‑terminus, single‑Cys, or a dedicated handle) and linker (stable or cleavable; project‑dependent) are selected to preserve peptide function, protect payload integrity, and support the intended release or stability hypothesis. [1], [2]

Bio‑Synthesis delivers chemically defined PDC synthesis by attaching drug payloads to a chosen peptide site (N‑/C‑terminus, single‑Cys, or handle-enabled chemistry) to minimize heterogeneity and support structure–function studies. [1], [3]

site-specific peptide–drug conjugation
reduced heterogeneity
1:1 payload control (typical)
ISO 9001:2015 / ISO 13485:2016
45+ Years of Expertise
U.S. Facilities – Texas

From a practical standpoint, site specificity can simplify purification and analytical confirmation because a single dominant conjugate species is expected (sequence and payload dependent). This can help teams compare payloads, linker concepts, or peptide variants with fewer confounding variables during optimization. [2], [3]

Branched peptide synthesis schematic showing a lysine branching core with two to eight peptide arms (MAP-2, MAP-4, MAP-8) and dendrimer for multivalent epitope presentation.

Schematic illustration of a site-specific peptide–antibody conjugate using defined linker chemistry, highlighting Fc-binding peptide attachment via a thioester linker.

Bio-Synthesis service focus: We integrate custom peptide synthesis, conjugation chemistry, purification, and fit‑for‑purpose analytical confirmation (e.g., HPLC/UPLC purity profiling and LC–MS when feasible) to support discovery-stage and preclinical PDC programs.

Related: Peptide–drug conjugation services · Cleavable linker PDCs

Why choose site-specific PDC synthesis?

Cleaner product definition

Defined attachment reduces mixtures from multiple reactive sites and supports consistent characterization.

Better reproducibility

A single attachment site helps reduce batch-to-batch variability during research programs.

Clearer structure–function readouts

Uniform constructs make it easier to interpret binding, uptake, release, and activity differences.

Site-specific attachment strategies (concepts)

The best route depends on the peptide sequence, payload chemistry, desired linker behavior, and intended application. Below are common strategies used in PDC development (project-dependent).

N-terminal / C-terminal attachment clean definition • simple architecture
N-terminus C-terminus amide coupling
  • Often used when terminal modification does not disrupt peptide binding or transport function.
  • Compatible with many stable linker designs; cleavable designs possible depending on payload and handling needs.
  • Common starting point for discovery-stage PDC structure–function studies.
Single-cysteine (Cys) thiol-selective conjugation high selectivity • defined 1:1
single-Cys thiol-selective maleimide / disulfide (concepts)
  • Introduce or utilize a unique cysteine to enable selective coupling and reduce heterogeneity.
  • Useful for stable or cleavable concepts (e.g., disulfide-based) depending on design goals.
  • Attachment site is chosen to minimize impact on peptide function (project-dependent).
Handle-enabled / bioorthogonal strategies high control • advanced designs
azide/alkyne (concept) click-ready orthogonal
  • Use a dedicated handle to enable highly selective conjugation in complex architectures.
  • Often chosen when multiple modifications are needed or when selectivity is critical.
  • Feasibility depends on peptide, payload, and downstream constraints (project-dependent).

Linker options (stable vs cleavable)

The linker connects peptide and payload and can be designed for stability or controlled release. Linker selection is informed by payload chemistry, desired release hypothesis (if any), and expected handling conditions (project-dependent).

Non-cleavable (stable) concepts
  • Amide-based linkages for high stability
  • Thioether concepts (project-dependent)
  • Stable spacer designs to reduce steric interference
Cleavable concepts (project-dependent)
  • Enzyme-cleavable motifs (e.g., dipeptide + spacer concepts)
  • Redox-cleavable disulfide concepts
  • pH-labile concepts (payload/handling dependent)

For deeper details, see Cleavable linker PDCs.

Workflow: from design to delivery

1) Design scoping

Sequence review, attachment site selection, linker plan, and payload compatibility checks (project-dependent).

2) Build & conjugate

Custom peptide synthesis + controlled conjugation route to minimize heterogeneity.

3) Purify & confirm

Purification and fit-for-purpose analytical confirmation aligned to research needs.

Fastest quoting tip: Share peptide sequence(s), payload structure or catalog #, preferred attachment site/constraints, desired linker behavior, quantity/purity targets, and intended use.

QC & deliverables

Standard analytical confirmation
  • Analytical HPLC/UPLC purity profile
  • LC–MS identity confirmation (when feasible)
  • COA + method summary
Heterogeneity controls
  • Defined attachment site planning
  • Process controls to minimize side-products (project-dependent)
  • Documentation aligned to intended use
Optional study support

If you need release or stability checks, share conditions and time window.

  • Condition-specific monitoring (project-dependent)
  • Intact conjugate verification
  • Cleavable concept checks (if required)

Our Quality Commitment

Bio-Synthesis follows controlled workflows and quality practices aligned with Total Quality Management (TQM). For site-specific PDCs, emphasis is placed on attachment-site control, payload compatibility, purification strategy, and fit-for-purpose analytical confirmation.

  • Purity profiling: analytical HPLC/UPLC
  • Identity confirmation: LC–MS when feasible
  • Reproducibility: site-defined attachment to reduce heterogeneity
  • Documentation: COA and method summary aligned to intended use

Contact & quote request

For the fastest quote on site-specific peptide–drug conjugation services, share your peptide sequence(s), payload structure or catalog #, preferred attachment site/constraints, linker preference (or ask for a recommendation), and quantity/purity targets.

Fastest path
Request a Quote Speak to a Chemist
Fast quote checklist
  • Peptide sequence(s) + termini state + reactive handles (Cys/Lys/azide/alkyne)
  • Payload name + structure (or catalog #) + any solubility constraints
  • Attachment site preference (or “recommend best site”)
  • Linker preference (stable vs cleavable; if cleavable, what trigger)
  • Quantity (mg), purity target, intended use, and timeline constraints

Speak to a Scientist

Full Name *
Email *
Company / Institution *
Phone *
Notes *Please avoid confidential details; we can arrange an NDA if needed.

By submitting, you agree to be contacted regarding your request.

972-420-8505 (USA) 800-227-0627 (INTL.) info@biosyn.com Contact Us

Recommended Reading & Literature References

These peer‑reviewed publications provide scientific context for site‑selective bioconjugation, linker design, and small‑molecule payload attachment concepts used in peptide–drug conjugate (PDC) research.

  • Hoyt, E. A.; Cal, P. M. S. D.; Oliveira, B. L.; Bernardes, G. J. L. Contemporary approaches to site-selective protein and peptide bioconjugation. Nat. Rev. Chem. 2019, 3, 147–171. DOI
  • Chudasama, V.; Maruani, A.; Caddick, S. Recent advances in the construction of antibody–drug conjugates. Nat. Chem. 2016, 8, 114–119. DOI
  • Dubowchik, G. M.; Walker, M. A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther. 1999, 83, 67–123. (background on targeted release concepts)
  • Krall, N.; da Cruz, F. P.; Boutureira, O.; Bernardes, G. J. L. Site-selective protein–drug conjugation for synergistic anti-cancer therapy. Nat. Chem. 2016, 8, 103–113. DOI

E‑E‑A‑T note: References are included to support scientific context for conjugation concepts and do not imply clinical claims. Bio‑Synthesis provides custom synthesis and conjugation support; feasibility and methods are selected on a project‑specific basis.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 40+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links